PTO/SB/81 (07-08)

Approved for use through 12/31/2008. OMB 0651-0035

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

POWER OF ATTORNEY OR REVOCATION OF POWER OF ATTORNEY WITH A NEW POWER OF ATTORNEY AND

CHANGE OF CORRESPONDENCE ADDRESS

d to respond to a collection of into	rmation unless it displays a valid Olvib control flumber.
Application Number	10/616,694
Filing Date	July 9, 2003
First Named Inventor	Adams et al.
Title	Methods and Compositions Relating to Isoleucine Boroproline Compounds
Art Unit	1654
Examiner Name	David Lukton
Attorney Docket Number	I0248.70023US00/9442-48

I hereby revoke all previous powers of attorney given in the above-identified application.							
A Power of Attorney is submitted herewith.							
X Number as my/or identified above,	I hereby appoint Practitioner(s) associated with the following Customer		20792				
OR I hereby appoint Practitioner(s) named below as my/our attorney(s) or agent(s) to prosecute the application identified above, and to transact all business in the United States Patent and Trademark Office connected therewith:							
F	Practitioner(s) Name		Registration Number				
					-		
					<u> </u>		
Please recognize or change the correspondence address for the above-identified application to:							
The address ass	The address associated with the above-mentioned Customer Number.						
OR							
X The address associated with Customer Number:			20792				
OR							
Firm or Individual Name							
Address							
		01-1-		1 7in			
City		State	<u> </u>	Zip			
Country Telephone		Email					
I am the:							
Applicant/Inventor. OR							
Assignee of record of the entire interest, See 37 CFR 3.71. Statement under 37 CFR 3.73(b) (Form PTO/SB/96) submitted herewith or filed on							
SIGNATURE of Applicant or Assignee of Record							
Signature	GHE EN		Date	(919) 861-0198			
Name	John Didsbury, Ph.D.		Telephone				
Title and Company							
NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below*.							
X *Total of 1	forms are submitted.						

This collection of information is required by 37 CFR 1.31, 1.32 and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Adams et al.

Assignee:

DARA BioSciences, Inc. (Amended)

Title:

METHODS AND COMPOSITIONS RELATING TO

ISOLEUCINE BOROPROLINE COMPOUNDS

Serial No.:

10/616,694

Filed:

July 9, 2003

Examiner:

David Lukton

Group Art Unit:

1654

Atty. Docket No.:

10248.70023US00/9442-48

COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, VA 22313-1450

STATEMENT UNDER 37 C.F.R. § 3.73(b) ESTABLISHING RIGHT OF ASSIGNEE TO TAKE ACTION

DARA BioSciences, Inc. is the assignee of the entire interest in the above-identified application by virtue of (1) a Patent Assignment from the inventors of the above-identified application to Point Therapeutics, Inc. and (2) a change in the name of the assignee from Point Therapeutics Inc. to DARA BioSciences, Inc.

The Patent Assignment from the inventors to Point Therapeutics, Inc. is recorded at reel 014858, frame 0061 on January 7, 2004.

A copy of the Certificate of Amendment to Certificate of Incorporation of Point Therapeutics, Inc. ("Certificate of Amendment") that was filed with the Delaware Secretary of State on February 12, 2008 and amended the assignee's name from Point Therapeutics, Inc. to DARA BioSciences, Inc. is enclosed herewith. The Certificate of Amendment is being submitted concurrently for recordation pursuant to 37 C.F.R. § 3.11.

The assignee seeks to take action in the Patent and Trademark Office in this matter. The undersigned is empowered to sign this Statement on behalf of the assignee.

Rv.

John Didsbury, Ph.D.

President, Chief Operating Officer &

Chief Scientific Officer DARA BioSciences, Inc.

Date

7/31/08

Delaware

PAGE .

The First State

I, HARRIET SMITH WINDSOR, SECRETARY OF STATE OF THE STATE OF DELAWARE, DO HEREBY CERTIFY THE ATTACHED IS A TRUE AND CORRECT COPY OF THE CERTIFICATE OF AMENDMENT OF "POINT THERAPEUTICS, INC.", CHANGING ITS NAME FROM "POINT THERAPEUTICS, INC." TO "DARA BIOSCIENCES, INC.", FILED IN THIS OFFICE ON THE TWELFTH DAY OF FEBRUARY, A.D. 2008, AT 12:16 O'CLOCK P.M.

A FILED COPY OF THIS CERTIFICATE HAS BEEN FORWARDED TO THE NEW CASTLE COUNTY RECORDER OF DEEDS.

AND I DO HEREBY FURTHER CERTIFY THAT THE EFFECTIVE DATE OF THE AFORESAID CERTIFICATE OF AMENDMENT IS THE TWELFTH DAY OF FEBRUARY, A.D. 2008, AT 4:03 O'CLOCK P.M.

2366172 8100

080146969

Warriet Smith Hinds
Harriet Smith Windsor, Secretary of State

AUTHENTICATION: 6376615

DATE: 02-12-08

You may verify this certificate online at corp.delaware.gov/authver.shtml

State of Delaware Secretary of State Division of Corporations Delivered 12:16 PM 02/12/2008 FILED 12:16 PM 02/12/2008 SRV 080146969 - 2366172 FILE

CERTIFICATE OF AMENDMENT TO CERTIFICATE OF INCORPORATION OF POINT THERAPEUTICS, INC.

Point Therapeutics, Inc., a Delaware corporation (the "Corporation"), does hereby certify that:

FIRST: This Certificate of Amendment (this "Certificate of Amendment") amends the Corporation's Certificate of Incorporation, as amended (the "Certificate of Incorporation").

SECOND: The terms and provisions of this Certificate of Amendment have been duly adopted in accordance with Section 242 of the General Corporation Law of the State of Delaware and shall become effective at 4:03 p.m., Eastern Standard Time, on February 12, 2008.

THIRD: Article FIRST of the Corporation's Certificate of Incorporation is hereby amended to read in its entirety as follows:

"The name of the Corporation is DARA BioSciences, Inc."

IN WITNESS WHEREOF, the Corporation has caused this Certificate of Amendment to be signed by its duly authorized officer this 12th day of February, 2008.

By:

POINT THER

Gerela